Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) saw a downside of -3.69% to close Friday at $7.82 after subtracting -$0.3 on the day. The 5-day average trading volume is 934,220 shares of the company’s common stock. It has gained $8.94 in the past week and touched a new high 1 time within the past 5 days. An average of 779,160 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,049,156.
ARQT’s 1-month performance is -24.52% or -$2.77 on its low of $7.82 reached on 08/18/23. The company’s shares have touched a 52-week low of $7.25 and high of $27.40, with the stock’s rally to the 52-week high happening on 03/01/23. YTD, ARQT has lost -47.16% or -$6.98 and has reached a new high 10 times. However, the current price is down -71.46% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
ARQT stock investors last saw insider trading activity on May 31.Matsuda Masaru (See Remark) most recently sold 1,830 shares at $7.80 per share on May 31. This transaction cost the insider $14,278. Director, Welgus Howard G., sold 8,500 shares at a price of $13.97 on Apr 17. Then, on Apr 06, Director Welgus Howard G. sold 8,500 shares at a price of $12.01 per share. This transaction amounted to $102,085.
Valuation Metrics
ARQT stock has a beta of 0.69. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 42.79 while the price-to-book (PB) in the most recent quarter is 5.97.
Arcutis Biotherapeutics Inc.’s quick ratio for the period ended June 29 was 8.10, with the current ratio over the same period at 8.40. As well, the company’s long term debt to equity for the quarter ending June 29 was 2.48, while the total debt to equity was 2.48. In terms of profitability, the gross margin trailing 12 months is 80.20%. The trailing 12-month EBITDA margin is -8149.05%. The firm’s gross profit as reported stood at $2.93 million against revenue of $3.69 million.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 5.04% to -$70.99 million, while revenue of -$80.1 million was -12.83% off the previous quarter. Analysts expected ARQT to announce -$1.25 per share in earnings in its latest quarter, but it posted -$1.16, representing a 7.20% surprise. EBITDA for the quarter stood at more than -$68.2 million. ARQT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 240.18 million, with total debt at $204.22 million. Shareholders hold equity totaling $61.65 million.
Let’s look briefly at Arcutis Biotherapeutics Inc. (ARQT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 18 August was 19.46% to suggest the stock is trending oversold, with historical volatility in this time period at 58.67%.
The stock’s 5-day moving average is $8.26, reflecting a -12.72% or -$1.14 change from its current price. ARQT is currently trading -25.45% above its 20-day SMA, -24.15% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -18.80% and SMA200 by-55.77%.
Stochastic %K and %D was 6.06% and 7.26% and the average true range (ATR) pointed at 0.60. The RSI (14) points at 29.21%, while the 14-day stochastic is at 0.00% with the period’s ATR at 0.63. The stock’s 9-day MACD Oscillator is pointing at -0.70 and -1.17 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), Needham launched coverage with a Buy rating. Analysts offering their rating for ARQT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate ARQT as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is ARQT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $22.00 and a high of $57.00, with their median price target at $44.50. Looking at these predictions, the average price target given by analysts is for Arcutis Biotherapeutics Inc. (ARQT) stock is $41.88.
